A young person with Duchenne muscular dystrophy died ... gene therapy delandistrogene moxeparvovec (Elevidys), Sarepta ...

Sarepta Therapeutics said early Tuesday that a patient had died after receiving its gene therapy Elevidys, which treats the ...

after acknowledging the sudden death of a patient with Duchenne muscular dystrophy (DMD) following treatment with the company’s marketed gene therapy. The patient, whom Sarepta described as a ...

A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 in Gene Therapy suggests the body’s natural immune system might be ...

In March, Sarepta Therapeutics, Inc. SRPT shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy ... especially after the recent patient death due to ...

Shares of Sarepta Therapeutics SRPT plunged nearly 24% last week after the company reported the death of a patient following treatment with Elevidys, its one-shot gene therapy for Duchenne ...